Abstract
Figure S4 shows that addition of an orthogonal anti–PD-1 antibody to INBRX-105-a resulted in enhanced antitumor activity in mouse tumor models and improved blockade of PD-1/PD-L1 interactions compared with INBRX-105-a alone